Global Information
회사소개 | 문의 | 비교리스트

세계의 뇌혈관 질환 치료 시장 : 예측(2022-2028년)

Global Cerebrovascular Diseases Treatment Research and Forecast 2022-2028

리서치사 Orion Market Research Pvt Ltd
발행일 2022년 08월 상품코드 1123248
페이지 정보 영문 110 Pages 배송안내 2-3일 (영업일 기준)
가격
US $ 5,125 ₩ 7,409,000 Unprintable PDF (Single User License)
US $ 6,625 ₩ 9,578,000 Printable PDF (Corporate License)


세계의 뇌혈관 질환 치료 시장 : 예측(2022-2028년) Global Cerebrovascular Diseases Treatment Research and Forecast 2022-2028
발행일 : 2022년 08월 페이지 정보 : 영문 110 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 뇌혈관 질환 치료 시장 규모는 예측 기간(2022-2028년)에 5.9%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다. 기술 진보, 뇌졸중 유병률 증가, 신흥 국가의 의료 인프라 확충과 지출은 뇌혈관 질환 치료 시장 성장에 크게 기여하는 주요인이 될 것으로 추정됩니다.

세계의 뇌혈관 질환(Cerebrovascular Diseases) 치료 시장에 대해 조사분석했으며, 시장 개요, 경쟁 구도, 시장 분석, 기업 프로파일 등의 정보를 제공합니다.

목차

카테고리 : 바이오테크놀러지 1. 보고서 개요

  • 조사 방법과 툴
  • 시장 내역
    • 부문별
    • 지역별

제2장 시장 개요와 인사이트

  • 조사 범위
  • 애널리스트 인사이트와 현재 시장 동향

제3장 경쟁 구도

  • 주요 기업 분석
    • 개요
    • 재무 분석
    • SWOT 분석
    • 최근 개발
  • 주요 전략 분석

제4장 시장 결정 요인

  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제5장 시장 세분화

  • 세계의 뇌혈관 질환 치료 시장 : 뇌졸중 유형별
    • 허혈성
    • 출혈성
  • 세계의 뇌혈관 질환 치료 시장 : 치료별
    • 투약
    • 외과적 시술
  • 세계의 뇌혈관 질환 치료 시장 : 최종사용자별
    • 병원
    • 외과 클리닉
    • 연구기관

제6장 지역 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 이탈리아
    • 스페인
    • 프랑스
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 기타 아시아태평양
  • 세계 기타 지역

제7장 기업 개요

  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Johnson & Johnson Services, Inc.
  • Medtronic plc
  • Merck & Co., Inc.
  • Penumbra, Inc.
  • Pfizer Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Siemens Healthineers AG
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • United Therapeutics Corp.
LSH 22.09.21

LIST OF TABLES

  • 1. GLOBAL CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE OF STROKE, 2020-2027($ MILLION)
  • 2. GLOBAL ISCHEMIC MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLION)
  • 3. GLOBAL HEMORRHAGIC MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLION)
  • 4. GLOBAL CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 5. GLOBAL MEDICATION MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLION)
  • 6. GLOBAL SURGICAL PROCEDURE MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLION)
  • 7. GLOBAL CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY END USER, 2020-2027($ MILLION)
  • 8. GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLION)
  • 9. GLOBAL SURGICAL CLINICS MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLION)
  • 10. GLOBAL RESEARCH INSTITUTIONS MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLION)
  • 11. NORTH AMERICAN CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 12. NORTH AMERICAN CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE OF STROKE, 2020-2027($ MILLION)
  • 13. NORTH AMERICAN CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 14. NORTH AMERICAN CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY END USER, 2020-2027($ MILLION)
  • 15. EUROPEAN CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 16. EUROPEAN CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE OF STROKE, 2020-2027($ MILLION)
  • 17. EUROPEAN CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 18. EUROPEAN CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY END USER, 2020-2027($ MILLION)
  • 19. ASIA PACIFIC CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 20. ASIA PACIFIC CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS, BY TYPE OF STROKE, 2020-2027($ MILLION)
  • 21. ASIA PACIFIC CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)

22. ASIA PACIFIC CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY END USER, 2020-2027($ MILLION

  • 23. REST OF WORLD CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE OF STROKE, 2020-2027($ MILLION)
  • 24. REST OF THE WORLD CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 25. REST OF THE WORLD CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY END USER, 2020-2027($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CEREBROVASCULAR DISEASE TREATMENT MARKET SHARE BY TYPE OF STROKE, 2020 VS 2027 (%)
  • 2. GLOBAL CEREBROVASCULAR DISEASE TREATMENT MARKET SHARE BY TREATMENT, 2020 VS 2027 (%)
  • 3. GLOBAL CEREBROVASCULAR DISEASE TREATMENT MARKET SHARE BY END USER, 2020 VS 2027 (%)
  • 4. GLOBAL CEREBROVASCULAR DISEASE TREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 5. GLOBAL ISCHEMIC TREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 6. GLOBAL HAEMORRHAGIC TREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 7. GLOBAL CEREBROVASCULAR DISEASE TREATMENT THROUGH MEDICATION MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 8. GLOBAL CEREBROVASCULAR DISEASE TREATMENT THROUGH SURGICAL PROCEDURES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL HOSPITAL SCEREBROVASCULAR DISEASE TREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 10. GLOBAL SURGICAL CLINIC SCEREBROVASCULAR DISEASE TREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 11. GLOBAL RESEARCH INSTITUTION SCEREBROVASCULAR DISEASE TREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 12. US CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 13. CANADA CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 14. 2020-2027 UK CEREBROVASCULAR DISEASE TREATMENT SIZE 2020-2027($ MILLION)
  • 15. GERMANY CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 16. SPAIN CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 17. FRANCE CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 18. ITALY CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 19. REST OF EUROPE CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 20. 2020-2027 CHINA CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 21. INDIA CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 22. JAPAN CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 23. REST OF ASIA PACIFIC CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 24. REST OF WORLD CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)

Cerebrovascular Diseases Treatment Market By Type of Stroke (Ischemic and Hemorrhagic), By Treatment (Medical and Surgical Procedure), By End User (Hospitals, Surgical Clinics, and Research Institutes) - Global Industry Share, Growth, Competitive Analysis, And Forecast, 2021-2027

The global cerebrovascular disease treatment market is expected to grow at a considerable CAGR of 5.9% during the forecast period. The major factors that are augmenting the growth of the cerebrovascular disease treatment market are advancement in technology and increasing prevalence of strokes. Furthermore, expansion and spending on healthcare infrastructure in the emerging economies, favorable medical reimbursements are also estimated to be the major factors that are contributing significantly towards the growth of the market. Above 85.0% of the strokes are of ischemic stroke which makes it most commonly caused due to less blood supply to the brain. In addition to this, several government organizations play an important role in the growth of the market. For instance, in 2016, the Society of Vascular and Interventional Neurology (SVIN) started a health campaign of Mission Thrombectomy 2020 to accelerate the access of stroke treatment globally by doubling the normal rate of treatment by 2020. The stroke diseases require early treatment as it is can be life-threatening due to some delay in treatment.

However, the lack of awareness among the people, the absence of skilled neurosurgeons and diagnostic centers, and the high cost of cerebrovascular treatment are some of the restraints that can challenge the growth of the market in the forecast period. Conversely, the high growth rate in healthcare infrastructure and the increasing number of research in the field are the opportunities that are expected to fuel the cerebrovascular diseases treatment market.

Segmental Outlook

The market is segmented on the basis of type of stroke, treatment, and end-user. By type of stroke, the market is segmented into ischemic and Hemorrhagic. The ischemic stroke treatment segment holds a significant market share during the forecast period. Ischemic stroke is driven by the high patient pool, growth in prevalence of stroke, and rise in R&D facilities. The ischemic stroke treatment major players include Bayer AG, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, and Medtronic. Moreover, based on the treatment segment, the market is segmented into medication and surgical procedures. Further, based on the end-user segment, the market is segmented into hospitals, surgical clinics, and research institutes.

Global Cerebrovascular disease treatment Market Share by type of stroke, 2020 (%)

Global Cerebrovascular disease treatment Market Share by type of stroke

Regional Outlooks

The global cerebrovascular disease treatment market is analyzed based on the geographical regions into North America, Europe, Asia Pacific, and the Rest of the World. North America is estimated to be one of the leading regions in the global cerebrovascular disease treatment market. Increase in R&D investments by the manufacturers, the rising level of hypertension and migraine, advancement and availability of technologies, and government initiatives are the major factor driving the growth of the market in this region. The US is estimated to have the highest share of the market in this region due to the high penetration of patented drugs in the country.

Global Cerebrovascular disease treatment Market Growth, by Region 2021-2027

Global Cerebrovascular disease treatment Market Growth, by Region

Asia Pacific is estimated to among the fastest-growing region during the forecast period. The factors promoting the growth of the market in the region include increasing awareness related to heart diseases, increasing disposable income, and increasing incidences related to heart disease due to unhealthy lifestyles. Moreover, favorable government policies to expand healthcare infrastructure in the region such as in China, India, and ASEAN and growth in medical tourism is also driving the market growth.

Market Players Outlook

Key players of the cerebrovascular disease treatment market are Abbott Laboratories, Pfizer Inc., Bristol-Myers Squibb Co., Bayer AG, Amgen Inc., Penumbra, Inc., and Johnson & Johnson Services, Inc. In order to survive in the market, these players adopt different marketing strategies such as mergers, acquisitions, product launches, and geographical expansion so on. For Instance, in October 2020, Bayer AG acquired Asklepios BioPharmaceutical to broaden its platform and potential for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases.

The Report Covers

Market value data analysis of 2019 and forecast to 2026.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global cerebrovascular disease treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Cerebrovascular Disease Treatment Market, By Type of Stroke
    • 5.1.1. Ischemic
    • 5.1.2. Haemorrhagic
  • 5.2. Global Cerebrovascular Disease Treatment Market, By Treatment
    • 5.2.1. Medication
    • 5.2.2. Surgical Procedure
  • 5.3. Global Cerebrovascular Disease Treatment Market, By End User
    • 5.3.1. Hospitals
    • 5.3.2. Surgical Clinics
    • 5.3.3. Research Institutions

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. Amgen Inc.
  • 7.3. AstraZeneca plc
  • 7.4. Bayer AG
  • 7.5. Boehringer Ingelheim International GmbH
  • 7.6. Bristol-Myers Squibb Co.
  • 7.7. Daiichi Sankyo Co. Ltd.
  • 7.8. F. Hoffmann-La Roche Ltd.
  • 7.9. Genentech, Inc.
  • 7.10. Johnson & Johnson Services, Inc.
  • 7.11. Medtronic plc
  • 7.12. Merck & Co., Inc.
  • 7.13. Penumbra, Inc.
  • 7.14. Pfizer Inc.
  • 7.15. Sangamo Therapeutics, Inc.
  • 7.16. Sanofi SA
  • 7.17. Siemens Healthineers AG
  • 7.18. Sihuan Pharmaceutical Holdings Group Ltd.
  • 7.19. Takeda Pharmaceutical Co. Ltd.
  • 7.20. United Therapeutics Corp.
Back to Top
전화 문의
F A Q